High grade serous carcinoma (HGSC) is the most common and most aggressive subtype of ovarian cancer, accounting for roughly 70% of all ovarian cancer cases. Despite being called “ovarian” cancer, strong evidence now shows it usually originates not on the surface of the ovary but in the lining of the fallopian tube. Most cases are diagnosed at an advanced stage, when the cancer has already spread beyond the pelvis, which is a major reason it carries such a serious prognosis.
Where It Actually Starts
For decades, scientists assumed HGSC arose from cells on the ovary’s surface. That view has been overturned. Whole-genome studies show that HGSC tissue closely matches the gene expression patterns of normal fallopian tube lining, not ovarian tissue. No precursor lesion for HGSC has ever been found on the ovary itself.
Instead, the earliest identifiable precursor is a tiny, non-invasive tumor called a serous tubal intraepithelial carcinoma, or STIC. These lesions form in the fimbriae, the finger-like projections at the open end of the fallopian tube closest to the ovary. In women who underwent surgery for advanced-stage disease, STICs were found in the fallopian tubes in 67% of cases, and 92% of those were confined to the fimbriated end. STICs carry the same TP53 gene mutations found in the full-blown cancer, confirming a direct clonal relationship. At some point, additional genetic changes allow cells from a STIC to detach, implant on the ovary or peritoneal surfaces, and grow into clinically recognizable HGSC.
Genetic Features That Define HGSC
The single most defining molecular feature of HGSC is mutation of the TP53 gene, which controls a protein that normally suppresses tumor growth. The Cancer Genome Atlas found TP53 mutations in over 96% of HGSC specimens. This near-universal presence is so characteristic that pathologists treat the absence of a TP53 abnormality as a reason to question the diagnosis.
Beyond TP53, about 20% of patients carry mutations in the BRCA1 or BRCA2 genes, either inherited (germline) or acquired by the tumor itself (somatic). These mutations impair a specific DNA repair process called homologous recombination. When this repair pathway is broken, cancer cells become especially vulnerable to a class of drugs called PARP inhibitors, which exploit that weakness. Testing for this repair deficiency, known as homologous recombination deficiency or HRD, has become a standard part of treatment planning.
HGSC tumors also tend to have a high number of copy number changes across their chromosomes, meaning large stretches of DNA are gained or lost. This genomic instability distinguishes HGSC from its slower-growing counterpart, low grade serous carcinoma, which has a more stable genome and a completely different set of driver mutations.
How It Is Diagnosed
Diagnosis typically involves imaging, surgery, and tissue analysis. When a pathologist examines tissue under the microscope, HGSC has a characteristic appearance: solid sheets or papillary structures of cells with large, irregular nuclei and frequent cell division. But microscopic appearance alone isn’t always enough to distinguish it from other ovarian cancer subtypes, so pathologists rely on a panel of protein markers detected through staining techniques.
The most important marker is the p53 protein, the product of the TP53 gene. In HGSC, p53 staining shows one of several abnormal patterns: intense staining in over 80% of tumor cells (overexpression), complete absence of staining (null pattern), or staining confined to the cytoplasm with none in the nucleus. Any of these patterns signals a TP53 mutation. A normal, scattered staining pattern would point away from HGSC. Pathologists also look for positivity with WT1 (a marker of serous origin) and diffuse p16 staining, both typical of HGSC. Low grade serous tumors stain positive for WT1 but show normal p53 patterns, while endometrioid carcinomas are WT1-negative and show a mosaic p16 pattern, helping to distinguish these look-alikes.
Staging: How Far It Has Spread
HGSC is staged using the FIGO system, which applies to all ovarian, fallopian tube, and primary peritoneal cancers. The stage reflects how far the disease has traveled from its origin.
- Stage I: Cancer confined to the ovary or fallopian tube. This is uncommon in HGSC because the disease tends to spread silently before causing symptoms.
- Stage II: Cancer has extended to other pelvic structures such as the uterus or other pelvic tissues, but remains below the pelvic brim.
- Stage III: Cancer has spread to the peritoneum (the membrane lining the abdomen) outside the pelvis, or to retroperitoneal lymph nodes. This is the most common stage at diagnosis. Substages distinguish microscopic spread from visible deposits, with IIIC indicating peritoneal deposits larger than 2 cm.
- Stage IV: Distant metastasis, including fluid around the lungs containing cancer cells (IVA) or spread to organs like the liver, spleen (into the tissue itself, not just the surface), or lymph nodes outside the abdomen (IVB).
The majority of HGSC patients are diagnosed at Stage III or IV. In one study of long-term survivors with advanced HGSC, 77% had been diagnosed at Stage III and 23% at Stage IV.
First-Line Treatment
Standard treatment for advanced HGSC combines surgery and chemotherapy. The goal of surgery, called cytoreductive or debulking surgery, is to remove every visible tumor deposit. The ideal outcome is “complete debulking,” meaning no residual disease left behind. The amount of tumor remaining after surgery is one of the strongest predictors of how well a patient will do.
Chemotherapy follows (or sometimes precedes) surgery and is built around a platinum-based drug combined with a taxane, given in cycles typically spaced three weeks apart. This combination remains the backbone of HGSC treatment because the cancer tends to be highly sensitive to platinum-based therapy initially.
For patients whose tumors respond well to this first round of chemotherapy, maintenance therapy with a PARP inhibitor is now a standard option. PARP inhibitors work by blocking a backup DNA repair pathway. In cells that already have defective homologous recombination (due to BRCA mutations or other causes of HRD), this creates a lethal level of DNA damage the cancer cell cannot survive. Major international guidelines recommend HRD testing for all patients with advanced HGSC to determine who is most likely to benefit from these drugs.
Recurrence and Platinum Sensitivity
Most patients with advanced HGSC will eventually experience a recurrence, even after a strong initial response. How the cancer is treated at recurrence depends largely on how long it stayed in remission after the first platinum-based chemotherapy.
If the cancer returns six months or more after completing platinum therapy, it is classified as platinum-sensitive. These patients can be re-treated with platinum-based chemotherapy and typically respond again, though each successive remission tends to be shorter. If the cancer returns in less than six months, it is classified as platinum-resistant, and a different approach is needed. Non-platinum drugs, sometimes combined with an anti-angiogenic drug (bevacizumab) that cuts off the tumor’s blood supply, become the primary options. The most challenging scenario is platinum-refractory disease, where the cancer progresses during treatment or within one month of finishing it.
This classification system, while widely used, is imperfect. Some patients labeled platinum-resistant may still benefit from a platinum rechallenge, particularly if their treatment-free interval was longer than three months. Clinical decision-making increasingly incorporates molecular information alongside these time-based categories.
Survival and Long-Term Outlook
Prognosis for HGSC depends heavily on stage at diagnosis and how much tumor can be removed surgically. For advanced disease (Stages III and IV), roughly one in four patients survives beyond five years. In one study of 195 patients with advanced HGSC, 24.6% lived longer than five years, while 21.5% survived less than two years. The gap between these groups is influenced by factors including stage, residual disease after surgery, BRCA mutation status (BRCA-mutated tumors tend to respond better to platinum and PARP inhibitors), and overall health.
Patients diagnosed at earlier stages have substantially better outcomes, but early-stage HGSC is uncommon. The cancer produces vague symptoms, such as bloating, pelvic pressure, and changes in appetite or bowel habits, that overlap with many benign conditions. No reliable screening test exists for the general population. For women at high genetic risk, particularly those carrying BRCA1 or BRCA2 mutations, preventive removal of the fallopian tubes and ovaries significantly reduces the chance of developing this disease, a strategy that makes even more sense now that the fallopian tube is understood to be the primary site of origin.